In the first half of 2025, Mercator Medical increased its consolidated sales revenue by more than 14% year-on-year to nearly PLN 291 million, compared with the same period last year. Net profit amounted to PLN 21.4 million, up from PLN 4.95 million a year earlier. The improved results were driven by higher sales and a stronger gross margin on the company’s product range. The Group sold a total of 2.9 billion gloves, marking a 6.7% y/y increase.
– In a demanding and highly competitive market environment, we are able to effectively respond to emerging challenges and take advantage of new opportunities. The entire first half of the year was strongly influenced by U.S. customs policy and announcements, which reduced the competitiveness of Chinese suppliers and enabled us to achieve significant sales growth in the American market. At the same time, redirected U.S. volumes put pressure on the European market, causing considerable price pressure. We maintained stable business fundamentals while consistently expanding our product portfolio, as demonstrated by increased sales of nonwoven products – said Monika Żyznowska, CEO of Mercator Medical S.A.
The United States has become Mercator Medical’s largest market this year, with sales in the first half exceeding PLN 105.7 million (+73.1% y/y). This substantial growth was the result of active U.S. tariff regulations, which drove higher orders in the market while limiting the competitiveness of Chinese manufacturers.
The Mercator Medical Group also continued to strengthen its position in Central and Eastern Europe by expanding its product portfolio.
– The results for the first half confirm that the Group is systematically improving its financial standing. The noticeable increase in revenue and higher EBITDA are the result of an improved gross margin in the first months of the year and effective performance in sales and distribution. The significant increase in net profit from nearly PLN 5 million to PLN 21.4 million was also made possible by a positive result in financial operations and a change in deferred tax. This stemmed from an individual tax interpretation obtained by the Company regarding foreign exchange differences on loan conversions and repayments – emphasized Mariusz Popek, Management Board Member of Mercator Medical S.A.
Looking ahead, the Group plans to further strengthen its position in key markets and expand its product portfolio. As part of its business diversification strategy, it will also continue its activities in the real estate sector through its subsidiary Mercator Estates, which is carrying out development projects.
Source: CEO.com.pl
